{"entity":{"id":"nct02174549","kind":"trial","name":"Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer","aka":[],"tldr":"A phase 1/2 trial of Tirapazamine in hepatocellular carcinoma and neuroendocrine tumours, run by Teclison Ltd., now recruiting.","summary":"Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer is a phase 1/2 interventional study registered as NCT02174549 by Teclison Ltd., with 25 participants planned, started 2014-09 and due to reach its primary completion in 2028-03-31. Interventions recorded: Tirapazamine and Conventional Transarterial Embolization (TAE).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02174549","url":"https://clinicaltrials.gov/study/NCT02174549"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc","neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02174549","phase":"1/2","setting":"Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer","sponsor":"Teclison Ltd.","enrolled":25,"outcomes":[]},"route":"/trials/nct02174549/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}]}}